J 2017

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

BLANAROVA, O., Barbora ŠAFAŘÍKOVÁ, Jarmila HERŮDKOVÁ, Martin KRKOŠKA, S. TOMANKOVA et. al.

Basic information

Original name

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

Authors

BLANAROVA, O. (203 Czech Republic), Barbora ŠAFAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Jarmila HERŮDKOVÁ (703 Slovakia, belonging to the institution), Martin KRKOŠKA (203 Czech Republic, belonging to the institution), S. TOMANKOVA (203 Czech Republic), Z. KAHOUNOVA (203 Czech Republic), L. ANDERA (203 Czech Republic), J. BOUCHAL (203 Czech Republic), G. KHARAISHVILI (203 Czech Republic), M. KRAL (203 Czech Republic), P. SOVA (203 Czech Republic), Alois KOZUBÍK (203 Czech Republic, belonging to the institution) and A. HYRŠLOVÁ VACULOVÁ (203 Czech Republic, guarantor)

Edition

Plos one, San Francisco, Public Library of Science, 2017, 1932-6203

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.766

RIV identification code

RIV/00216224:14310/17:00100456

Organization unit

Faculty of Science

UT WoS

000416402000040

Keywords in English

X-LINKED INHIBITOR; PLATINUM(IV) COMPLEX LA-12; CYTOCHROME-C; ANTITUMOR EFFICACY; IN-VITRO; DEATH; LIGAND; THERAPY; PROTEIN; MANNER

Tags

Tags

International impact, Reviewed
Změněno: 30/3/2018 08:33, Ing. Nicole Zrilić

Abstract

V originále

Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or LA-12, and related molecular mechanisms. We demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. This was accompanied by augmented Bid cleavage, Bak activation, loss of mitochondrial membrane potential, activation of caspase-8, -10, -9, and -3, and XIAP cleavage. RNAi-mediated silencing of Bid or Bak in Bax-deficient DU 145 cells suppressed the drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling. The caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage. Importantly, we newly demonstrated LA-12-mediated enhancement of TRAIL-induced cell death in cancer cells derived from human patient prostate tumor specimens. Our results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action.